Abstract

In 1976 we heralded the introduction of bromocriptine (Parlodel - Sandoz) as "an important advance" for the treatment of patients with hyperprolactinaemia.1 Now two new drugs are available for treating hyperprolactinaemia; cabergoline (▼Dostinex - Pharmacia) which the manufacturer claims offers "a significant advance in prolactin control" and quinagolide (▼Norprolac - Sandoz) for which the claim is of a "significant advance in the therapy of hyperprolactinaemia". Do these newer products hold real advantages?